Pembrolizumab Associated Pericardial Effusion In A Patient With Advanced Esophageal Cancer

Akesh Thomas^1*, Emmitt Lee Turner¹, Lawrence Sevilla Parwan¹ and Sajin M Karakattu²

¹Department of Internal Medicine, East Tennessee State University, Johnson City, USA

²Department of Critical Care, East Tennessee State University, Johnson City, USA

*Corresponding Author:

Akesh Thomas
Department of Internal Medicine
East Tennessee State University
325 N State of Franklin, Johnson City, USA
E-mail: thomasa16@etsu.edu

Received: September 28, 2020 Accepted: February 25, 2021 Published: March 10, 2021

Citation: Thomas A, Turner EL, Parwan LS, Karakattu SM (2021) Pembrolizumab Associated Pericardial Effusion in a Patient with Advanced Esophageal Cancer. Clin Oncol Case Rep 4:3

Pembrolizumab is an Immune Checkpoint Inhibitor (ICI) that exerts anti-tumor activity by inhibiting the interaction of programmed cell death protein 1 with its ligand (PD-L1) on activated lymphocytes.Immune Related adverse effects are a major concern for the use of ICI. We are reporting the case of a 64 year old white male with advanced esophageal adenocarcinoma who presented with moderate pericardial effusion after receiving treatment with pembrolizumab. The patient was treated with systemic steroids which improved his condition. Clinicians should consider the possibility of Immure related adverse effects in patients receiving immunotherapy with a wide array of presentations.